



ASX release

7 July 2016

Large National Plan to Reimburse SphygmoCor Test *US covered lives increase to more than 126 million*

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which noninvasively measures the central arterial pressure waveform, central aortic blood pressures and arterial stiffness indices, today announced that a large US national health insurance plan provider for more than 35 million lives has initiated reimbursement of the SphygmoCor test. With this addition, health plans covering over 126 million lives are now reimbursing physicians using the test.

AtCor Medical CEO, Duncan Ross, said: "We are very pleased with the rate at which health plans are supporting reimbursement for the SphygmoCor test. Reimbursement is now provided for doctors covering over 40% of US insured lives. This enables tens of millions of patients to benefit from noninvasive central arterial pressure waveform analysis, and supports our commercial launch to doctors after the Category 1 CPT code became available.

"We are continuing to work with a leading private reimbursement consultant to educate payers, and discussions continue with other medical insurance plans to support reimbursement of the SphygmoCor test."

AtCor is initially targeting four major metropolitan areas through its specialist sales force supported by a telemarketing campaign. The rollout is proceeding as planned.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811
p.manley@atcormedical.com

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m.0407 231 282 or
a.rambukwella@fcr.com.au